Pronota awarded EUR 1.4 million grant to validate and develop novel cardiovascular biomarkers
The grant will be used to validate and biologically characterize in great detail novel candidate protein markers discovered using Pronota’s proprietary MASStermindTM platform. In addition, the grant supports the development of generic immuno-based assays for the lead candidates, which will be used for the final clinical validation in a large, multicenter, clinical trial and the regulatory submission.
Commenting on the grant, Dr Koen Kas, founder and CSO of Pronota said: "This award, which follows on the heels of the 2009 series B fundraising, totaling EUR 6.4 million, provides us with the means to address a significant clinical and commercial opportunity which should prove the era of clinical proteomics has finally arrived”.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.